Evidence map›Paper›PMID 39780996›Full record

ArticleBulletin of the World Health Organization2025

Establishing links between drug registers and essential medicines lists.

Petra Brhlikova, Zaheer-Ud-Din Babar, Allyson M Pollock

Abstract read
In one paragraph

Article in Bulletin of the World Health Organization, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Petra BrhlikovaPopulation Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Newcastle upon TyneNE2 4AX, England.
Zaheer-Ud-Din BabarCollege of Pharmacy, Qatar University, Doha, Qatar.
Allyson M PollockPopulation Health Sciences Institute, Newcastle University, Baddiley-Clark Building, Newcastle upon TyneNE2 4AX, England.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Access to essential medicines is still suboptimal in many countries. Recent studies examining the registration of medicines at the country level show that a considerable proportion of essential medicines do not have any corresponding products registered for use at the country level and therefore cannot be available at all times. Conversely, many non-essential medicines are registered by regulatory authorities for local markets, potentially facilitating inappropriate drug use and antimicrobial resistance. Addressing this public health gap requires linking the data on national drug registers with national essential medicines lists. Achieving this linkage will necessitate the development of common data variables and standards for both drug registers and essential medicines lists. This linkage would provide medicines regulators and health policy-makers with information on the gaps in the registration of essential medicines and allow them to take steps to prioritize registration of these medicines. This approach would improve availability of essential medicines for public health priorities and prevent over-registration of unnecessary medicines.

Indexed as

Drugs, EssentialRegistriesHealth Services AccessibilityHumansWorld Health OrganizationDrugs, Essential

Identifiers

PMID39780996
PMCPMC11704638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.